Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects.

Yunona Khomitskaya, Nadezhda Tikhonova,Konstantin Gudkov, Svetlana Erofeeva,Victoria Holmes,Brian Dayton,Nigel Davies,David W Boulton,Weifeng Tang

Clinical Therapeutics（2018）

引用 13|浏览2

暂无评分

摘要

Bioequivalence of dapagliflozin/metformin XR FCDP and the individual components was established without any new safety concerns, presenting a safe alternative for patients currently receiving regimens including each component individually. ClinicalTrials.gov identifier: NCT02722239.

查看译文

关键词

bioequivalence,dapagliflozin,fixed-combination drug product,metformin,Russian Federation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要